Combined SGLT2 and GLP-1 Therapy Lowers Risk for CVD, Kidney Disease in Type 2 Diabetes

Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

People with type 2 diabetes and chronic kidney disease have a high risk for kidney failure and cardiovascular (CV) complications. Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors (SGLT2i) independently reduce CV and kidney events. The effect of combining both is unclear. FLOW trial participants with type 2 diabetes and chronic kidney disease were stratified by baseline SGLT2i use (N = 550) or no use (N = 2,…

Combined SGLT2 and GLP-1 therapy lowers risk for CVD, kidney disease in type 2 diabetes

Combined SGLT2 inhibitor and GLP-1 receptor agonist therapy could provide additional cardiovascular and renal benefits for adults with type 2 diabetes, according to data from a meta-analysis published in The Lancet Diabetes & Endocrinology. “These data represent the largest and most comprehensive evaluation of the effects of SGLT2 inhibitors on clinical outcomes with and without GLP-1

Study Highlights Cardiopulmonary Benefits of GLP-1 RAs in Patients with Diabetes, OSA

New research has indicated that glucagon-like peptide-1 receptor agonists result in lower all-cause mortality and risk of cardiovascular events in patients with concurrent sleep apnea and type 2 diabetes.